Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Final Results from the Phase III TeloVac Trial in Pancreatic Cancer

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
Results from the trial showed no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy.

The TeloVac trial was sponsored by The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK and was funded by Cancer Research UK. The trial was conducted through the Cancer Research UK Liverpool Clinical Trials Unit and supported by GemVax, a subsidiary of KAEL-GemVax. The trial recruited 1062 patients in 52 centres throughout the UK. There was no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy. The trial also included an ambitious program of translational research, which is still undergoing evaluation. Initial results indicate that the vaccine resulted in a significant anti-inflammatory response that correlates well with new research being conducted by the parent company, Kael-GemVax. Additionally, two possible biomarkers for an increased survival in response to the vaccine in a subgroup of patients were identified.

J.P. Neoptolemos (Cancer Research UK Liverpool Clinical Trials Unit Director and National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, UK) commented on the trial:

“This large trial in a needy and difficult group of patients was extremely well received and recruited well ahead of target providing a wealth of clinical and scientific information. Although the two vaccine arms did not show an overall significant survival advantage compared to background chemotherapy, we were delighted to see that the vaccine was well tolerated without significant side effects. We were very pleased that using the combination of gemcitabine and capecitabine produced such a good one year survival rate.

In general, we have identified that simultaneous vaccination with chemotherapy provides an effective method for generating both an immune response and also promoting an anti-inflammatory effect. We are encouraged by the finding of potential biomarkers that may serve to identify a group of patients that could respond to the vaccine with improved survival. These findings are sufficiently strong to initiate new basic research into the mechanisms of action of the vaccine and test the use of GV1001 in future clinical trials aiming to improve survival of a subgroup of patients using the biomarkers identified in this trial”.

Michelle Kim, Kael-GemVax CEO said “While we are disappointed that the vaccine did not result in a significant survival advantage, we are encouraged by the finding of two possible biomarkers that may predict response to the vaccine and increased survival in a subgroup of patients. Furthermore, we are excited to see that an anti-inflammatory effect was seen in the trial, a finding that reinforces research that is currently being conducted at Kael-GemVax”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genetic Chaos in Tumours Could Help Predict Chemo Response
Researchers have shown how the level of genetic chaos in tumours could help predict patients’ response to chemotherapy according to new research.
Friday, August 07, 2015
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Tuesday, August 04, 2015
‘Liquid Biopsies’ Could Help Spot Genetic Faults in Lung Cancer
Study analyze blood samples from 97 patients who took part in the EURTAC clinical trial.
Saturday, March 07, 2015
New Companies Join Cancer Research UK Consortium
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.
Thursday, December 11, 2014
Why Bowel Cancer Sometimes Outsmarts Treatment
New study challenges the prevailing view of how bowel cancer develops in the large intestine.
Tuesday, December 02, 2014
Cancer Cell Fingerprints in the Blood May Speed up Childhood Cancer Diagnosis
Researchers found unique molecular fingerprints for 11 types of children’s tumours, to develop blood tests to diagnose these cancers.
Tuesday, November 04, 2014
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner
Partnership Developed to Trial Immunotherapy Vaccine For Lung Cancer
Friday, September 12, 2014
Cancer Research UK, Astellas Partner on Cancer Treatments
The new collaboration will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.
Friday, August 08, 2014
New Route to Boost Pancreatic Cancer Treatment
Cancer Research UK scientists have uncovered new insights into how the key pancreatic cancer drug gemcitabine is broken down in tumour cells.
Monday, June 02, 2014
Cancer Research UK, AZ and Pfizer Partner to Advance Lung Cancer Treatment
Partnership creates a pioneering clinical trial for patients with advanced lung cancer, marking a new era of research into personalised medicines to treat cancer.
Thursday, April 17, 2014
Astronomy Algorithms Help Diagnose Aggressive Tumors
Scientists have honed techniques originally developed to spot distant galaxies and used them to identify biomarkers that signal a cancer’s aggressiveness among some 2,000 breast tumours.
Monday, February 25, 2013
Study Points to Potential New Treatment for Deadly Pancreatic Cancer
Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.
Tuesday, May 01, 2012
Scientists Find New Drug Target for Hard-to-Treat Leukaemia
Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival.
Friday, March 30, 2012
Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates
Eden Biodesign to provide process development and manufacturing services for two of CR-UK’s gene therapy products for head and neck cancer.
Thursday, September 06, 2007
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!